Literature DB >> 3092225

Abnormal response to DNA crosslinking agents of Fanconi anemia fibroblasts can be corrected by transfection with normal human DNA.

C Diatloff-Zito, D Papadopoulo, D Averbeck, E Moustacchi.   

Abstract

Primary skin fibroblast cell lines from patients with Fanconi anemia were cotransfected with UV-irradiated pSV2neo plasmids and high molecular weight DNA from normal human cells. Restoration of a normal cellular resistance to mitomycin C (MMC) was observed provided that a Fanconi anemia cell line is selected for DNA-mediated transformation (neo gene) and that at least two successive rounds of transfection are performed. Cells were selected by taking advantage of the higher proliferation rate and plating efficiency of the MMC resistant transformants. As estimated from reconstruction experiments, the frequency of transfer of MMC resistance lies between 1 and 30 X 10(-7). The MMC resistance phenotype was maintained for at least 10 generations following transfection. Evidence for DNA-mediated transformation also includes the recovery of a normal pattern of DNA semiconservative synthesis after treatment with 8-methoxypsoralen and 365-nm UV irradiation, and the presence of exogenous pSV2neo DNA sequences was shown by Southern blot analysis. The acquired MMC resistance is probably due to the presence of DNA from normal cells. Indeed, sensitivity to MMC was maintained when Fanconi anemia cells were cotransfected with the UV-irradiated pSV2neo plasmid mixed with their own DNA or with yeast or salmon sperm DNA. These negative results also render unlikely the selection of spontaneous MMC resistant revertants in transfection of Fanconi anemia cells with normal DNA. These experiments establish the prerequisites for the isolation of the gene(s) involved in the response to DNA crosslinking lesions in human cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3092225      PMCID: PMC386647          DOI: 10.1073/pnas.83.18.7034

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  45 in total

1.  Fractionation of DNA from mammalian cells by alkaline elution.

Authors:  K W Kohn; L C Erickson; R A Ewig; C A Friedman
Journal:  Biochemistry       Date:  1976-10-19       Impact factor: 3.162

2.  Susceptibility of Fanconi's anaemia fibroblasts to chromosome damage by carcinogens.

Authors:  A D Auerbach; S R Wolman
Journal:  Nature       Date:  1976-06-10       Impact factor: 49.962

3.  Antagonistic effect of cocultivation on mitomycin C-induced aberration rate in cells of a patient with Fanconi's anemia and in Chinese hamster ovary cells.

Authors:  S Zakrzewski; K Sperling
Journal:  Hum Genet       Date:  1980       Impact factor: 4.132

4.  Carcinogen-induced chromosome breakage in Fanconi's anaemia heterozygous cells.

Authors:  A D Auerbach; S R Wolman
Journal:  Nature       Date:  1978-01-05       Impact factor: 49.962

5.  Competence for DNA transfer of ouabain resistance and thymidine kinase: clonal variation in mouse L-cell recipients.

Authors:  C M Corsaro; M L Pearson
Journal:  Somatic Cell Genet       Date:  1981-09

6.  DNA-mediated transfer of the adenine phosphoribosyltransferase locus into mammalian cells.

Authors:  M Wigler; A Pellicer; S Silverstein; R Axel; G Urlaub; L Chasin
Journal:  Proc Natl Acad Sci U S A       Date:  1979-03       Impact factor: 11.205

7.  DNA repair in human cells containing photoadducts of 8-methoxypsoralen or angelicin.

Authors:  J Kaye; C A Smith; P C Hanawalt
Journal:  Cancer Res       Date:  1980-03       Impact factor: 12.701

8.  DNA repair in a Fanconi's anemia fibroblast cell strain.

Authors:  A J Fornace; J B Little; R R Weichselbaum
Journal:  Biochim Biophys Acta       Date:  1979-01-26

9.  DNA crosslinking and cell survival in human lymphoid cells treated with 8-methoxypsoralen and long wavelength ultraviolet radiation.

Authors:  L F Cohen; K H Kraemer; H L Waters; K W Kohn; D L Glaubiger
Journal:  Mutat Res       Date:  1981-02       Impact factor: 2.433

10.  Specific cellular defects in patients with Fanconi anemia.

Authors:  R Weksberg; M Buchwald; P Sargent; M W Thompson; L Siminovitch
Journal:  J Cell Physiol       Date:  1979-11       Impact factor: 6.384

View more
  6 in total

1.  Partial complementation of the Fanconi anemia defect upon transfection by heterologous DNA. Phenotypic dissociation of chromosomal and cellular hypersensitivity to DNA cross-linking agents.

Authors:  C Diatloff-Zito; F Rosselli; J Heddle; E Moustacchi
Journal:  Hum Genet       Date:  1990-12       Impact factor: 4.132

2.  Abnormal lymphokine production: a novel feature of the genetic disease Fanconi anemia. I. Involvement of interleukin-6.

Authors:  F Rosselli; J Sanceau; J Wietzerbin; E Moustacchi
Journal:  Hum Genet       Date:  1992-04       Impact factor: 4.132

Review 3.  Identification of human genes involved in repair and tolerance of DNA damage.

Authors:  B Kaina; G Fritz; T Coquerelle
Journal:  Radiat Environ Biophys       Date:  1991       Impact factor: 1.925

4.  Transfection of normal human and Chinese hamster DNA corrects diepoxybutane-induced chromosomal hypersensitivity of Fanconi anemia fibroblasts.

Authors:  M Shaham; B Adler; S Ganguly; R S Chaganti
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

5.  Dynamin impacts homology-directed repair and breast cancer response to chemotherapy.

Authors:  Sophia B Chernikova; Rochelle B Nguyen; Jessica T Truong; Stephano S Mello; Jason H Stafford; Michael P Hay; Andrew Olson; David E Solow-Cordero; Douglas J Wood; Solomon Henry; Rie von Eyben; Lei Deng; Melanie Hayden Gephart; Asaithamby Aroumougame; Claudia Wiese; John C Game; Balázs Győrffy; J Martin Brown
Journal:  J Clin Invest       Date:  2018-10-29       Impact factor: 14.808

6.  Mutagenesis by third-strand-directed psoralen adducts in repair-deficient human cells: high frequency and altered spectrum in a xeroderma pigmentosum variant.

Authors:  M Raha; G Wang; M M Seidman; P M Glazer
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-02       Impact factor: 11.205

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.